A Phase I Study of IMP321 and Gemcitabine as the Front-line Therapy in Patients with Advanced Pancreatic Adenocarcinoma

PURPOSE: This phase I study was conducted to determine the safety profile and maximum tolerated dose (MTD) of IMP321, a soluble lymphocyte activation gene-3 (LAG-3) Ig fusion protein and MHC Class II agonist, combined with gemcitabine in patients with advanced pancreatic adenocarcinoma. PATIENTS AND...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wang-Gillam, Andrea, Plambeck-Suess, Stacey, Goedegebuure, Peter, Simon, Peter O, Mitchem, Jonathan B, Hornick, John R, Sorscher, Steven, Picus, Joel, Suresh, Rama, Lockhart, Albert C, Tan, Benjamin, Hawkins, Williams
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3760728/
https://ncbi.nlm.nih.gov/pubmed/22864469
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9866-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados